TY - JOUR
T1 - The exomes of the NCI-60 panel
T2 - A genomic resource for cancer biology and systems pharmacology
AU - Abaan, Ogan D.
AU - Polley, Eric C.
AU - Davis, Sean R.
AU - Zhu, Yuelin J.
AU - Bilke, Sven
AU - Walker, Robert L.
AU - Pineda, Marbin
AU - Gindin, Yevgeniy
AU - Jiang, Yuan
AU - Reinhold, William C.
AU - Holbeck, Susan L.
AU - Simon, Richard M.
AU - Doroshow, James H.
AU - Pommier, Yves
AU - Meltzer, Paul S.
PY - 2013/7/15
Y1 - 2013/7/15
N2 - The NCI-60 cell lines are the most frequently studied human tumor cell lines in cancer research. This panel has generated the most extensive cancer pharmacology database worldwide. In addition, these cell lines have been intensely investigated, providing a unique platform for hypothesis-driven research focused on enhancing our understanding of tumor biology. Here, we report a comprehensive analysis of coding variants in the NCI-60 panel of cell lines identified by whole exome sequencing, providing a list of possible cancer specific variants for the community. Furthermore, we identify pharmacogenomic correlations between specific variants in genes such as TP53, BRAF, ERBBs, and ATAD5 and anticancer agents such as nutlin, vemurafenib, erlotinib, and bleomycin showing one of many ways the data could be used to validate and generate novel hypotheses for further investigation. As new cancer genes are identified through large-scale sequencing studies, the data presented here for the NCI-60 will be an invaluable resource for identifying cell lines with mutations in such genes for hypothesisdriven research. To enhance the utility of the data for the greater research community, the genomic variants are freely available in different formats and from multiple sources including the CellMiner and Ingenuity websites.
AB - The NCI-60 cell lines are the most frequently studied human tumor cell lines in cancer research. This panel has generated the most extensive cancer pharmacology database worldwide. In addition, these cell lines have been intensely investigated, providing a unique platform for hypothesis-driven research focused on enhancing our understanding of tumor biology. Here, we report a comprehensive analysis of coding variants in the NCI-60 panel of cell lines identified by whole exome sequencing, providing a list of possible cancer specific variants for the community. Furthermore, we identify pharmacogenomic correlations between specific variants in genes such as TP53, BRAF, ERBBs, and ATAD5 and anticancer agents such as nutlin, vemurafenib, erlotinib, and bleomycin showing one of many ways the data could be used to validate and generate novel hypotheses for further investigation. As new cancer genes are identified through large-scale sequencing studies, the data presented here for the NCI-60 will be an invaluable resource for identifying cell lines with mutations in such genes for hypothesisdriven research. To enhance the utility of the data for the greater research community, the genomic variants are freely available in different formats and from multiple sources including the CellMiner and Ingenuity websites.
UR - http://www.scopus.com/inward/record.url?scp=84880861468&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880861468&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-12-3342
DO - 10.1158/0008-5472.CAN-12-3342
M3 - Article
C2 - 23856246
AN - SCOPUS:84880861468
SN - 0008-5472
VL - 73
SP - 4372
EP - 4382
JO - Cancer Research
JF - Cancer Research
IS - 14
ER -